Recommended Topic Related To:

Hycamtin

"The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, a"...

Hycamtin

PATIENT INFORMATION

Bone Marrow Suppression

Inform patients that HYCAMTIN decreases blood cell counts such as white blood cells, platelets, and red blood cells. Patients who develop fever, other signs of infection (e.g., chills, cough, or burning pain on urination), or bleeding while on therapy should notify their physician promptly. Inform patients that frequent blood tests will be performed while taking HYCAMTIN to monitor for the occurrence of bone marrow suppression.

Pregnancy And Breastfeeding

Advise patients to use effective contraceptive measures to prevent pregnancy and to avoid breastfeeding during treatment with HYCAMTIN.

Asthenia And Fatigue

Inform patients that HYCAMTIN may cause asthenia or fatigue. If these symptoms occur, caution should be observed when driving or operating machinery.

Last reviewed on RxList: 3/18/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Hycamtin - User Reviews

Hycamtin User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Hycamtin sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.